Jerusalem, Israel, October 12, 2015 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that Novartis will invest up to an additional $15 million in the Company in current and future equity. The investment will be used to …